Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study

This podcast features two of the investigators from the international, randomized, phase III EMBARK trial (NCT02319837) in conversation. The findings from EMBARK led to the subsequent approval of enzalutamide by the US Food and Drug Administration for nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence (BCR) at high risk for metastasis, and by the European Medicines Agency for patients with high-risk BCR nmCSPC who are unsuitable for salvage radiotherapy. Treatment guidelines have now been updated accordingly to reflect these approvals. In this first of a series of podcasts about EMBARK, the speakers discuss the background and rationale for the EMBARK trial, including the unmet medical need in this patient population, and examine some notable features of the study design.